Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Undiscovered Gems Highlight 3 Top Small Cap Stocks with Strong Metrics

In This Article:

In the current economic landscape, cooling inflation in the U.S. and strong bank earnings have propelled major stock indexes higher, while small-cap stocks, as evidenced by the S&P MidCap 400's notable gains, are also capturing attention amidst this positive momentum. With these dynamics in play, identifying small-cap stocks with robust financial metrics can be a strategic move for investors looking to capitalize on potential growth opportunities within this segment of the market.

Top 10 Undiscovered Gems With Strong Fundamentals

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Omega Flex

NA

0.39%

2.57%

★★★★★★

Wilson Bank Holding

NA

7.87%

8.22%

★★★★★★

SALUS Ljubljana d. d

13.55%

13.11%

9.95%

★★★★★★

Ovostar Union

0.01%

10.19%

49.85%

★★★★★★

MAPFRE Middlesea

NA

14.56%

1.77%

★★★★★☆

ASA Gold and Precious Metals

NA

7.11%

-35.88%

★★★★★☆

Sparta

NA

-5.54%

-15.40%

★★★★★☆

Pure Cycle

5.15%

-2.61%

-6.23%

★★★★★☆

Arab Banking Corporation (B.S.C.)

213.15%

18.58%

29.63%

★★★★☆☆

BOSQAR d.d

94.35%

39.11%

23.56%

★★★★☆☆

Click here to see the full list of 4658 stocks from our Undiscovered Gems With Strong Fundamentals screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Consun Pharmaceutical Group

Simply Wall St Value Rating: ★★★★★★

Overview: Consun Pharmaceutical Group Limited focuses on the research, development, manufacturing, and sale of Chinese medicines and medical contrast medium products in China, with a market capitalization of HK$6.44 billion.

Operations: The company generates revenue primarily from the Consun Pharmaceutical Segment, contributing CN¥2.33 billion, and the Yulin Pharmaceutical Segment, adding CN¥410 million.

Consun Pharma, a nimble player in the pharmaceuticals sector, has been trading at nearly 60% below its estimated fair value, suggesting potential undervaluation. Over the past year, earnings grew by 13.9%, surpassing the industry average of 9.4%, indicating robust performance. The company's debt-to-equity ratio has improved significantly from 27.7% to 12.7% over five years, reflecting effective financial management and reduced leverage risks. Recent changes in company bylaws aim to align with regulatory requirements and streamline governance structures, potentially enhancing operational efficiency moving forward while maintaining high-quality earnings and positive free cash flow.

SEHK:1681 Earnings and Revenue Growth as at Jan 2025
SEHK:1681 Earnings and Revenue Growth as at Jan 2025

Fujian Raynen Technology

Simply Wall St Value Rating: ★★★★★☆